[1] Metzger-Filho O, Sun Z, Viale G, et al.Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease:results from international breast cancer study group trials Ⅷ and Ⅸ[J].J Clin Oncol, 2013,31:3083-3090. [2] Zhang J, Laubacher JS, Ramirez MT, et al. The role of adjuvant chemotherapy in Luminal B breast cancer[J]. J Clin Oncol, 2014, 32(26-suppl):156. [3] 杨福兰, 倪军, 黄兴伟,等. TAC对luminal B型乳腺癌的新辅助化疗疗效观察与预后分析[J]. 实用临床医学, 2016, 17(3):32-35. [4] Goldhirsch A, Winer E, Coates A, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol,2013,24(9):2206-2223. [5] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol,2011,22(8):1736-1747. [6] Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined Luminal A breast cancer[J]. J Clin Oncol, 2013, 31(2):203-209. [7] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]. 中国癌症杂志, 2017, 27(9):695-760. [8] Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. [9] Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J]. Breast, 2003, 12(5):320-327. [10] Bonnefoi H, Litière S, Piccart M, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes:a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase Ⅲ trial[J]. Ann Oncol, 2014,25(6):1128-1136. [11] Cortazar P, Zhang L, Untch M, et al. Abstract S1-11:Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)[J]. Cancer Res, 2012,72(24):S1-11. [12] Nishimukai A, Yagi T, Yanai A, et al. High Ki-67 expression and low progesterone receptor epression culd idependently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast bancer[J]. Clin Breast Cancer, 2015, 15(3):204-211. [13] Cancello G, Maisonneuve P, Rotmensz N, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse[J]. Ann Oncol,2013, 24(3):661-668. [14] Yu Z, Li Z, Wu J, et al. progesterone receptor status and Ki-67 index may predict early relapse in Luminal B/HER2 negative breast cancer patients:A retrospective study[J]. PLoS One, 2014, 9(8):e95629. [15] Hayashi N, Niikura N, Yamauchi H, et al. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer[J]. Breast Cancer Res Treat, 2013, 137(2):523-531. [16] Saura C, Bendell J, Jerusalem G, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy[J]. Clin Cancer Res, 2014, 20(7):1935-1945. [17] Vaz-Luis I, Seah D, Olson EM, et al. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy:a retrospective cohort study[J]. Clin Breast Cancer, 2013, 13(4):254-263. [18] Bonotto M, Gerratana L, Poletto E, et al. Measures of outcome in metastatic breast cancer:insights from a real-world scenario[J]. Oncologist, 2014, 19(6):608-615. [19] McGuire A, Kalinina O, Holian E, et al. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab[J]. Breast Cancer Res Treat, 2017, 164(1):221-229. [20] Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN Guidelines Insights:Breast Cancer, Version 1.2017[J]. J Natl Compr Cancer Netw, 2017, 15(4):433-451. [21] Masuda N. adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017,376(22):2147-2159. [22] Chen X, Du F, Hong R, et al. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative,metastatic breast cancer[J].Cancer, 2016, 35(6):46-52. |